This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sundaresan, P.
Right arrow Articles by Rabkin, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sundaresan, P.
Right arrow Articles by Rabkin, S. D.

 Previous Article  |  Next Article 

Journal of Virology, April 2000, p. 3832-3841, Vol. 74, No. 8
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation in Mice

Periasamy Sundaresan,1,dagger William D. Hunter,1,Dagger Robert L. Martuza,1 and Samuel D. Rabkin1,2,*

Molecular Neurosurgery Laboratory, Departments of Neurosurgery1 and Microbiology & Immunology,2 Georgetown University Medical Center, Washington, D.C. 20007

Received 9 September 1999/Accepted 6 January 2000

Herpes simplex virus type 1 (HSV-1) mutants that are attenuated for neurovirulence are being used for the treatment of cancer. We have examined the safety of G207, a multimutated replication-competent HSV-1 vector, in mice. BALB/c mice inoculated intracerebrally or intracerebroventricularly with 107 PFU of G207 survived for over 20 weeks with no apparent symptoms of disease. In contrast, over 80% of animals inoculated intracerebrally with 1.5 × 103 PFU of HSV-1 wild-type strain KOS and 50% of animals inoculated intracerebroventricularly with 104 PFU of wild-type strain F died within 10 days. Similarly, after intrahepatic inoculation of G207 (3 × 107 PFU) all animals survived for over 10 weeks, whereas no animals survived for even 1 week after inoculation with 106 PFU of KOS. After intracerebroventricular inoculation, LacZ expression was initially observed in the cells lining the ventricles and subarachnoid space; expression decreased until almost absent within 5 days postinfection, with no apparent loss of ependymal cells. G207 DNA could be detected by PCR in the brains of mice 8 weeks after intracerebral inoculation; however, no infectious virus could be detected after 2 days. As a model for latent HSV in the brain, we used survivors of an intracerebral inoculation of HSV-1 KOS at the 50% lethal dose. Inoculation of a high dose of G207 at the same stereotactic coordinates did not result in reactivation of detectable infectious virus or symptoms of disease. We conclude that G207 is safe at or above doses that were efficacious in mouse tumor studies.

* Corresponding author. Mailing address: Department of Neurosurgery, Georgetown University Medical Center, 3970 Reservoir Rd., NW, Washington, DC 20007. Phone: (202) 687-8047. Fax: (202) 687-3046. E-mail: rabkins{at}odrge.odr.georgetown.edu.

dagger Present address: Aravind Eye Hospital, Madurai-625 020, Tamilnadu, India.

Dagger Present address: Department of Neurological Surgery, University of Wisconsin, Madison, Wis.

Journal of Virology, April 2000, p. 3832-3841, Vol. 74, No. 8
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Huszthy, P. C., Goplen, D., Thorsen, F., Immervoll, H., Wang, J., Gutermann, A., Miletic, H., Bjerkvig, R. (2008). Oncolytic Herpes Simplex Virus Type-1 Therapy in a Highly Infiltrative Animal Model of Human Glioblastoma. Clin. Cancer Res. 14: 1571-1580 [Abstract] [Full Text]  
  • Braun, E., Zimmerman, T., Hur, T. B., Reinhartz, E., Fellig, Y., Panet, A., Steiner, I. (2006). Neurotropism of herpes simplex virus type 1 in brain organ cultures.. J. Gen. Virol. 87: 2827-2837 [Abstract] [Full Text]  
  • Barzon, L., Boscaro, M., Palu, G. (2004). Endocrine Aspects of Cancer Gene Therapy. Endocr. Rev. 25: 1-44 [Abstract] [Full Text]  
  • Fu, X., Zhang, X. (2002). Potent Systemic Antitumor Activity from an Oncolytic Herpes Simplex Virus of Syncytial Phenotype. Cancer Res. 62: 2306-2312 [Abstract] [Full Text]  
  • Yamamura, H., Hashio, M., Noguchi, M., Sugenoya, Y., Osakada, M., Hirano, N., Sasaki, Y., Yoden, T., Awata, N., Araki, N., Tatsuta, M., Miyatake, S.-I., Takahashi, K. (2001). Identification of the Transcriptional Regulatory Sequences of Human Calponin Promoter and Their Use in Targeting a Conditionally Replicating Herpes Vector to Malignant Human Soft Tissue and Bone Tumors. Cancer Res. 61: 3969-3977 [Abstract] [Full Text]  
  • Wu, A., Mazumder, A., Martuza, R. L., Liu, X., Thein, M., Meehan, K. R., Rabkin, S. D. (2001). Biological Purging of Breast Cancer Cells Using an Attenuated Replication-competent Herpes Simplex Virus in Human Hematopoietic Stem Cell Transplantation. Cancer Res. 61: 3009-3015 [Abstract] [Full Text]  
  • Todo, T., Martuza, R. L., Rabkin, S. D., Johnson, P. A. (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA 98: 6396-6401 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»